A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 74,000 shares at $36.09 ($2.7M) on 2024-09-16, disclosed to the SEC on 2024-09-17.
Open-market sale of $2.7M APLS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.09 | 29,476 | $1.1M | 39.7% |
| 2 | $36.09 | 29,476 | $1.1M | 39.7% |
| 3 | $36.79 | 7,524 | $277K | 10.3% |
| 4 | $36.79 | 7,524 | $277K | 10.3% |
| Total | $36.23 avg | 74,000 | $2.7M | 100% |
| Filing → |
| APLS | SELL | 2025-09-19 | $1.4M | — | Filing → |
| APLS | SELL | 2024-06-21 | $2.9M | — | Filing → |
| APLS | SELL | 2024-03-20 | $2.1M | — | Filing → |